OF
Highly rated in
25
conditions
Highly rated in
25
conditions
Check Dr. Olga Frankfurt's experience treating your condition:
About Dr. Olga Frankfurt

Olga Frankfurt is a Hematologist and a Hematologist Oncology expert in Chicago, Illinois. Frankfurt has been practicing medicine for over 23 years and is highly rated in 25 conditions, according to our data. Her top areas of expertise are Acute Myeloid Leukemia AML, Acute Myeloblastic Leukemia without Maturation, Acute Myeloblastic Leukemia with Maturation, and Acute Lymphoblastic Leukemia ALL. She is licensed to treat patients in Illinois. Frankfurt is currently accepting new patients.

Her clinical research consists of co-authoring 61 peer reviewed articles and participating in 2 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Olga Frankfurt it is best to call her office and ask if your insurance is accepted.


Dr. Olga Frankfurt accepts the following insurance:

  •  Blue Cross Blue Shield
  •  Cigna

Call to see if your plan is accepted.
Locations
233 E Superior St, Chicago, IL 60611
Other Locations
233 E Superior St, Chicago, IL 60611
Background & Education
Graduate Institution
University Of Chicago, Pritzker School Of Medicine, 1999.0
Specialties
Hematology
Hematology Oncology
Licenses
Internal Medicine in IL
Hospital Affiliations
Northwestern Medicine Lake Forest Hospital
Northwestern Medicine Central DuPage Hospital
Northwestern Memorial Hospital
Languages Spoken
English
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


2 Clinical Trials

A Phase II Trial of Alemtuzumab (Campath-1H) and Rituximab (Rituxan) in Patients With Previously Untreated CLL
View 1 Less Clinical Trial -

61 Total Publications

Enasidenib vs conventional care in mutant-IDH2 relapsed/refractory acute myeloidleukemia: a randomized, phase 3 trial.
Summary: Enasidenib vs conventional care in mutant-IDH2 relapsed/refractory acute myeloidleukemia: a randomized, phase 3 trial.


Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors